The short answer
Panax ginseng has not been shown to alter alogliptin absorption or cause added hypoglycemia with it. Different preparations have produced different glucose findings in other settings.
What this answer covers
Asian Panax ginseng root and specific extracts; not American ginseng or every processed ginseng product.
- Supplement or preparation
- Panax ginseng
- Medication ingredient
- alogliptin
The glucose findings are mixed
Small acute Asian-ginseng studies were null or showed a higher two-hour glucose measure, while a specific vinegar extract improved HbA1c in drug-naive patients. Neither tested alogliptin.
Glucose measures do not establish a drug interaction
These results cannot show that alogliptin absorption changes or that the combination causes harmful lows. Species and extraction differences also prevent a predictable effect from the botanical name alone.
The diabetes regimen changes the context
Alogliptin works through glucose-dependent incretin effects. A monotherapy trial found a similar low frequency of hypoglycemia with alogliptin and placebo. Its label still calls for attention when insulin or a sulfonylurea is also used; this is not a supplement-specific risk estimate.
Review the product and glucose response
Discuss starting or stopping the supplement with the diabetes team, and follow the prescribed monitoring plan. Do not change alogliptin yourself or assume a short spacing gap prevents a glucose effect. Kidney function, rather than a botanical enzyme theory alone, is central to its dosing.
Evidence and practical considerations
Side effects & toxicity
No verified exact alogliptin clinical interaction. Original botanical preparations, other treatment regimens and null findings cannot establish the stated exposure/effectiveness or hypoglycemia claim.
- Exact scope
- Asian Panax ginseng root and specific extracts; not American ginseng or every processed ginseng product. with Oral alogliptin RxCUI 1368001 IN supplied as benzoate; limited metabolism and renal elimination retained.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured event rate, imported CYP effect size or arbitrary dose adjustment.
Factors that may matter: Preparation; Kidney function; Other glucose-lowering medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alogliptin
DPP-4 inhibition produces glucose-dependent effects. Most dose is excreted unchanged in urine; CYP metabolism is limited. With or without food. Hypoglycemia precautions especially with insulin/secretagogues; renal function determines dosing.
How this applies: Exact alogliptin active-moiety bridge from current benzoate tablet label.
Not metformin/pioglitazone combination products. No exact botanical interaction rate or automatic nutrient requirement. Limited CYP role precludes simple probe-drug transfer.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 329 treatment-naive type 2 diabetes participants.
Alogliptin improved glycemic control; hypoglycemia and overall adverse-event proportions were similar across active and placebo groups.
How this applies: Exact alogliptin relevance limited by original exposure and endpoint.
Monotherapy does not establish supplement co-use safety or zero hypoglycemia.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two groups of11healthy volunteers.
No significant overall glucose/insulin effect; pooled Asian-ginseng treatment had higher two-hour glucose than placebo.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure, efficacy interaction or clinical hypoglycemia measurement. Asian root/vinegar extract and American ginseng differ.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 72drug-naive adults with type 2 diabetes.
Vinegar-extracted Panax ginseng improved HbA1c in a small trial, with no severe adverse events reported in the abstract.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure, efficacy interaction or clinical hypoglycemia measurement. Asian root/vinegar extract and American ginseng differ.
Research assessment: · Open full citations ↗
Absorption & effectiveness
No verified exact alogliptin clinical interaction. Original botanical preparations, other treatment regimens and null findings cannot establish the stated exposure/effectiveness or hypoglycemia claim.
- Exact scope
- Asian Panax ginseng root and specific extracts; not American ginseng or every processed ginseng product. with Oral alogliptin RxCUI 1368001 IN supplied as benzoate; limited metabolism and renal elimination retained.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured event rate, imported CYP effect size or arbitrary dose adjustment.
Factors that may matter: Preparation; Kidney function; Other glucose-lowering medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alogliptin
DPP-4 inhibition produces glucose-dependent effects. Most dose is excreted unchanged in urine; CYP metabolism is limited. With or without food. Hypoglycemia precautions especially with insulin/secretagogues; renal function determines dosing.
How this applies: Exact alogliptin active-moiety bridge from current benzoate tablet label.
Not metformin/pioglitazone combination products. No exact botanical interaction rate or automatic nutrient requirement. Limited CYP role precludes simple probe-drug transfer.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 329 treatment-naive type 2 diabetes participants.
Alogliptin improved glycemic control; hypoglycemia and overall adverse-event proportions were similar across active and placebo groups.
How this applies: Exact alogliptin relevance limited by original exposure and endpoint.
Monotherapy does not establish supplement co-use safety or zero hypoglycemia.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two groups of11healthy volunteers.
No significant overall glucose/insulin effect; pooled Asian-ginseng treatment had higher two-hour glucose than placebo.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure, efficacy interaction or clinical hypoglycemia measurement. Asian root/vinegar extract and American ginseng differ.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 72drug-naive adults with type 2 diabetes.
Vinegar-extracted Panax ginseng improved HbA1c in a small trial, with no severe adverse events reported in the abstract.
How this applies: Indirect for alogliptin; original exposure and endpoint retained.
No alogliptin exposure, efficacy interaction or clinical hypoglycemia measurement. Asian root/vinegar extract and American ginseng differ.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact alogliptin article separating renal disposition, glucose effects and general husk timing. | |
| Research summary published |
Article revision: 9bfc8fb97ee13478
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.